<DOC>
	<DOCNO>NCT00732563</DOCNO>
	<brief_summary>RATIONALE : Diagnostic procedure use fludeoxyglucose F 18 surgical probe may help find lymph node metastasis patient early-stage non-small cell lung cancer . PURPOSE : This clinical trial study well fludeoxyglucose F 18 work detect lymph node metastasis patient stage I stage II non-small cell lung cancer remove surgery .</brief_summary>
	<brief_title>Fludeoxyglucose F 18 Detecting Lymph Node Metastasis Patients With Stage I Stage II Non-Small Cell Lung Cancer That Can Be Removed Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine positive threshold lymph node radioactivity fludeoxyglucose F 18 , utilize gamma probe , patient resectable stage I II non-small cell lung cancer . - Compare accuracy detect thoracic lymph node metastasis use positron emission tomography-computed tomography ( PET-CT ) versus intra-operative hand-held gamma probe patient . - Determine ability gamma probe detect lymph node micrometastases , result upstaging patient . - Assess clinical relevance gamma probe-detected lymph node metastases measure patient survival , tumor recurrence , impact patient quality life , cost . OUTLINE : Patients undergo positron emission tomography-computed tomography ( PET-CT ) scan within 90 day surgery . Beginning 1-4 hour surgery day 1 , patient receive injection fludeoxyglucose F 18 ( FDG ) mediastinoscopy perform . FDG-avid lymph node obtain may undergo immunohistochemical analysis standard analysis . Patients mediastinal lymph node micrometastasis undergo primary tumor resection . Patients ipsilateral mediastinal micrometastases undergo neoadjuvant chemotherapy prior surgical resection . Patients contralateral mediastinal micrometastases undergo definitive chemoradiotherapy . In absence mediastinal lymph node metastasis ( micro macro ) , complete surgical resection perform mediastinoscopy , include complete thoracic lymphadenectomy . The tumor lymph node ( mediastinoscopy thoracotomy ) undergo radioactivity measurement hand-held gamma probe . Fresh tumor lymph node sample store future study . Patients complete Short Form 36 Health Survey ( SF-36 ) surgery 1 , 3 , 6 month surgery assess potential impact gamma probe patient quality life . After completion study , patient follow every 6 month 2 year , annually 3 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis nonsmall cell lung cancer Stage III disease Resectable disease Planning undergo surgical resection No tumor fludeoxyglucose F 18 ( FDG ) avid PET scan PATIENT CHARACTERISTICS : Not pregnant Negative pregnancy test Fertile patient must use effective contraception No previous allergic reaction fludeoxyglucose F 18 No contraindication pulmonary lobectomy lymphadenectomy PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>stage I non-small cell lung cancer</keyword>
	<keyword>stage II non-small cell lung cancer</keyword>
</DOC>